United States Patent 7,361,650: Ivabradine Gamma-Crystal Patent Scope, Expiration, Litigation and Generic Risk
U.S. Patent No. 7,361,650 protects a specific gamma crystalline polymorph of ivabradine hydrochloride, processes for making that polymorph, pharmaceutical compositions containing it, and therapeutic use in angina, myocardial infarction and heart failure. The patent is a solid-state, formulation and method-of-use patent, not a basic compound patent. Its core U.S. patent term expired on November 22, 2022, based on the earliest applicable U.S. nonprovisional filing date. The patent therefore presents no current U.S. exclusionary barrier by itself, although other ivabradine patents, regulatory exclusivity, contractual restrictions or pending litigation can affect market entry. [1][2]
What does U.S. Patent 7,361,650 protect?
The patent has five claims divided across four protection categories:
| Claim |
Protected subject matter |
Practical scope |
| 1 |
Gamma crystalline ivabradine hydrochloride defined by powder X-ray diffraction |
Core polymorph claim |
| 2 |
Preparation using 2-ethoxyethanol, water, ethanol and controlled cooling |
Process claim |
| 3 |
Seeding during cooling under claim 2 |
Narrower process claim |
| 4 |
Pharmaceutical composition containing the gamma crystal |
Formulation claim |
| 5 |
Treatment of angina pectoris, myocardial infarction or heart failure |
Method-of-use claim |
The patent does not claim all ivabradine, all ivabradine hydrochloride, or every crystalline form. It targets one solid-state form identified as the gamma form.
How is the gamma form defined?
Claim 1 uses a powder X-ray diffraction profile rather than a simple chemical formula. The claimed material must exhibit the listed diffraction pattern, including prominent reflections at approximately:
- 4.2° 2θ
- 12.5° 2θ
- 13.4° 2θ
- 17.0° 2θ
- 21.1° 2θ
- 24.2° 2θ
- 24.5° 2θ
- 26.4° 2θ
- 28.0° 2θ
The claim lists 33 reflections, with associated peak height, area, full width at half height and interplanar distance. The strongest listed peaks are approximately 13.4°, 21.1°, 24.2° and 24.5° 2θ.
The reference to a PANalytical X'Pert Pro diffractometer and X'Celerator detector identifies the measurement conditions used in the patent. In an infringement or validity dispute, the central technical question would be whether the accused material is the same crystalline form, not whether its diffractogram reproduces every numerical value exactly under different equipment or sample conditions.
How strong is claim 1 covering the ivabradine polymorph?
Claim 1 is potentially broad in product coverage but narrow in subject matter. It covers the gamma polymorph regardless of how the polymorph is made or whether it is sold as a tablet, capsule or bulk active ingredient.
The claim’s commercial strength depends on four issues:
- Whether the accused product contains the gamma form.
- Whether the X-ray diffraction profile is materially consistent with the claimed pattern.
- Whether the gamma form is present in the final active pharmaceutical ingredient or finished dosage form.
- Whether the claim remains enforceable for the relevant sales period.
The phrase “essentially the following powder X-ray diffraction data” gives the claim some tolerance for normal analytical variation. It does not eliminate the need to establish the claimed crystalline identity. A generic manufacturer could seek to avoid literal infringement by using a different polymorph, amorphous ivabradine hydrochloride, a different salt, or a product that converts to the gamma form only after manufacture or storage. Such strategies would require analysis under the doctrine of equivalents and would depend on the patent’s prosecution history.
What are the principal validity risks?
The principal validity issues for the crystal claim would include:
- Anticipation by an earlier publication describing the same gamma form.
- Public use or commercial availability of the form before the effective filing date.
- Obviousness based on known ivabradine salts and routine crystallization screening.
- Insufficient written description if the full scope of the diffraction-defined form was not adequately supported.
- Enablement across the claimed analytical range.
- Indefiniteness associated with “essentially” and the effect of instrument, sample preparation and measurement conditions.
The patent’s detailed diffraction table supports written description and identification arguments. The strongest prior-art attack would ordinarily require a reference that discloses the same form, not merely ivabradine hydrochloride or a different polymorph.
What process is protected by claims 2 and 3?
Claim 2 covers a crystallization process using one of three solvent systems:
- Ivabradine hydrochloride and 2-ethoxyethanol.
- Ivabradine hydrochloride, 2-ethoxyethanol and water.
- Ivabradine hydrochloride, ethanol and water.
The process requires heating until dissolution is complete, cooling until crystallization is complete, and filtration to collect the product.
Claim 3 narrows claim 2 by requiring seeding during cooling. The claim does not appear to require a specific temperature, solvent ratio, seeding amount, cooling rate or filtration apparatus. Those omissions create a relatively broad process claim, but they also leave more room for invalidity arguments based on prior crystallization methods.
A process that produces the gamma polymorph through a different solvent system may avoid literal infringement of claim 2. It could still implicate claim 1 if the resulting active ingredient is the claimed gamma form.
What formulations are protected by claim 4?
Claim 4 covers a solid pharmaceutical composition containing the gamma crystalline form of ivabradine hydrochloride with one or more pharmaceutically acceptable, inert and non-toxic carriers.
The claim is not limited to a particular tablet strength, excipient, release profile, coating, granulation process or dosage form. It can therefore reach conventional solid oral dosage forms if the active ingredient is the claimed gamma polymorph.
The claim does not necessarily cover:
- A liquid formulation.
- A composition containing only a different ivabradine polymorph.
- A formulation in which the gamma form is absent or transformed.
- A product using ivabradine free base or another salt.
Because claim 4 depends on the polymorph in claim 1, a composition analysis would require both pharmaceutical formulation testing and solid-state characterization.
What uses are protected by claim 5?
Claim 5 covers administering the gamma crystalline form to treat:
- Angina pectoris.
- Myocardial infarction.
- Heart failure.
The wording covers treatment in a living animal body, including humans, and requires a therapeutically effective amount.
The claim is broader than a label limited to one indication, but enforcement against a generic product would depend on the approved label, prescribing information, product composition and induced-infringement evidence. The heart-failure indication is commercially important because U.S. Corlanor approval covers selected patients with stable heart failure and elevated heart rate. [3]
A generic product with an indication carve-out could reduce method-of-use exposure, but it would not avoid claim 1 or claim 4 if the generic uses the gamma polymorph.
When did U.S. Patent 7,361,650 expire?
| Event |
Date |
| Earliest priority filing in the patent family |
November 23, 2001 |
| U.S. nonprovisional/PCT-related filing basis |
November 22, 2002 |
| U.S. patent grant |
April 22, 2008 |
| Standard 20-year U.S. term |
November 22, 2022 |
| Current status |
Expired |
The 20-year U.S. patent term is generally calculated from the earliest effective nonprovisional filing date, not from the grant date. The patent therefore did not receive a new 20-year period beginning in 2008. USPTO records identify the patent as expired. [1][2]
What is the Orange Book status of ivabradine?
Ivabradine is marketed in the United States as Corlanor by Amgen under FDA-approved NDA 206143. The FDA approved Corlanor in April 2015 for specified patients with chronic heart failure and reduced ejection fraction, and later approved pediatric use in selected patients with cardiomyopathy. [3]
Patent listings in the FDA Orange Book are product-specific and can change through delisting, expiration or updates to approved use codes. U.S. Patent 7,361,650 should not be treated as a current Orange Book barrier merely because it was historically associated with ivabradine. Its patent term has expired. The relevant current assessment requires review of the live Orange Book entries for NDA 206143 and any corresponding use codes. [4]
What regulatory exclusivity protected Corlanor?
Corlanor received new chemical entity exclusivity when FDA approved the product in 2015. The ordinary five-year NCE period would have run from the approval date, subject to any pediatric exclusivity extension. FDA regulatory exclusivity is separate from patent rights and does not revive an expired patent.
For current generic-entry analysis, the critical distinction is:
| Protection |
Status |
| Compound patent protection |
Expired before U.S. Corlanor approval |
| U.S. Patent 7,361,650 |
Expired November 22, 2022 |
| Five-year NCE exclusivity |
Expired no later than 2020 |
| Possible pediatric extension |
Historical only |
| Biosimilar exclusivity |
Not applicable |
| Current generic barrier from Patent 7,361,650 |
None |
Ivabradine is a small molecule. A biosimilar pathway does not apply. Generic applicants use the ANDA pathway, subject to patent certifications and any unexpired listed patents. [3][4]
Which companies are challenging ivabradine exclusivity?
Publicly assessable generic competition must be analyzed through FDA-approved ANDAs, Orange Book certifications and federal Hatch-Waxman litigation records. The provided patent claim set does not establish a complete list of Paragraph IV filers or settlement parties.
The commercial risk is structurally high because the principal polymorph patent has expired and the product is a conventional small-molecule oral drug. A generic applicant could pursue one of three routes:
- Use the gamma polymorph after patent expiration.
- Use a non-gamma polymorph and avoid claim 1.
- Use a different manufacturing route while assessing composition and method claims separately.
A Paragraph IV challenge to this patent would have had limited economic value after the November 2022 expiration date unless it accelerated entry before expiration or supported a broader patent dispute. Any historical litigation should be checked against the ANDA case docket and the patent claims asserted, because a case involving a different ivabradine patent would not establish a dispute over Patent 7,361,650.
How does this patent compare with competing drug patent estates?
| Product |
Active ingredient |
Main U.S. estate type |
Biosimilar risk |
Generic-entry profile |
| Corlanor |
Ivabradine hydrochloride |
Polymorph, formulation and use patents |
None |
Small-molecule ANDA risk |
| Ranexa |
Ranolazine |
Compound, formulation and use patents |
None |
Small-molecule ANDA risk |
| Beta blockers |
Various |
Compound and formulation patents, mostly mature |
None |
Generally mature generic competition |
| Calcium-channel blockers |
Various |
Mature compound and formulation estates |
None |
High generic penetration |
Patent 7,361,650 is narrower than a compound patent but potentially more practical than a method claim while it was active. A polymorph claim can cover the commercial API itself, making it difficult to avoid without changing the solid-state form. Its value declines sharply after expiration because generic manufacturers can use the claimed form without infringement.
What manufacturing and geographic barriers remain?
The patent has no continuing U.S. exclusivity after expiration. During its term, it could have restricted manufacture, importation, sale or use of the gamma form in the United States under 35 U.S.C. §271. [5]
Foreign family members could have created separate barriers in Europe, Canada, Australia or other jurisdictions, but U.S. expiration does not determine foreign status. Each family member requires an independent review of:
- National filing and grant dates.
- Patent-term adjustments or extensions.
- Supplementary protection certificates.
- Local opposition or invalidity outcomes.
- Local generic approval and launch rules.
The process claims could have created manufacturing risk even where a supplier used a different final product description. After U.S. expiration, those claims no longer create current U.S. patent liability.
What is the revenue exposure from expiration?
Corlanor revenue is exposed to ordinary generic substitution and price erosion because:
- The product is an oral small molecule.
- The core polymorph patent has expired.
- FDA exclusivity is historical.
- The active ingredient does not require biosimilar development.
- A generic can potentially use the same commercially preferred crystal form without infringing Patent 7,361,650.
The remaining commercial defenses would come from brand loyalty, indication-specific labeling, supply reliability, physician familiarity, additional active patents, authorized-generic strategy and contracting. Patent 7,361,650 is no longer an effective defense against those pressures.
Key Takeaways
- U.S. Patent 7,361,650 covers the gamma crystalline polymorph of ivabradine hydrochloride.
- Claim 1 is the central product claim and is defined by a 33-peak powder X-ray diffraction profile.
- Claims 2 and 3 cover specified solvent-mediated crystallization processes, including seeded cooling.
- Claim 4 covers solid pharmaceutical compositions containing the gamma polymorph.
- Claim 5 covers treatment of angina, myocardial infarction and heart failure using the claimed form.
- The patent expired on November 22, 2022.
- It is not a current U.S. barrier to generic ivabradine entry.
- No biosimilar pathway applies because ivabradine is a small molecule.
- Current launch risk depends on other live patents, Orange Book listings, FDA exclusivity history and any active Hatch-Waxman litigation.
FAQs
Does Patent 7,361,650 cover all ivabradine hydrochloride?
No. It covers the gamma crystalline form identified by the specified powder X-ray diffraction pattern. Other polymorphs, amorphous material and different salts are outside the literal scope of claim 1.
Can a generic use the gamma form of ivabradine hydrochloride now?
Yes, the patent’s U.S. term expired in 2022. A generic applicant must still evaluate other unexpired patents, FDA requirements and applicable regulatory certifications.
Is claim 4 limited to Corlanor tablets?
No. Claim 4 is drafted broadly to cover a solid pharmaceutical composition containing the gamma form with pharmaceutically acceptable carriers. It is not limited to a particular brand, strength or excipient.
Does a different crystallization process avoid the patent?
A different process may avoid claims 2 and 3. It does not avoid claim 1 if the resulting product is the claimed gamma crystalline form.
Does the patent create biosimilar risk for Corlanor?
No. Ivabradine is a chemically synthesized small molecule. Competition proceeds through the ANDA generic-drug pathway rather than the biosimilar pathway.
References
-
United States Patent and Trademark Office. (2008). U.S. Patent No. 7,361,650, Crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it.
-
United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 7,361,650 patent term and status records.
-
U.S. Food and Drug Administration. (2015). FDA approves Corlanor to treat heart failure. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Code. (2024). 35 U.S.C. §271: Infringement of patent.
